ATE313560T1 - Therapeutische anti-cytomegalovirus verbindungen - Google Patents

Therapeutische anti-cytomegalovirus verbindungen

Info

Publication number
ATE313560T1
ATE313560T1 AT01918862T AT01918862T ATE313560T1 AT E313560 T1 ATE313560 T1 AT E313560T1 AT 01918862 T AT01918862 T AT 01918862T AT 01918862 T AT01918862 T AT 01918862T AT E313560 T1 ATE313560 T1 AT E313560T1
Authority
AT
Austria
Prior art keywords
compounds
cytomegalovirus
therapeutic anti
response
epitopes
Prior art date
Application number
AT01918862T
Other languages
English (en)
Inventor
Charles A Nicolette
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Application granted granted Critical
Publication of ATE313560T1 publication Critical patent/ATE313560T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT01918862T 2000-03-21 2001-03-19 Therapeutische anti-cytomegalovirus verbindungen ATE313560T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19105000P 2000-03-21 2000-03-21
US25498900P 2000-12-12 2000-12-12
PCT/US2001/008916 WO2001070766A2 (en) 2000-03-21 2001-03-19 Therapeutic anti-cytomegalovirus compounds

Publications (1)

Publication Number Publication Date
ATE313560T1 true ATE313560T1 (de) 2006-01-15

Family

ID=26886698

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01918862T ATE313560T1 (de) 2000-03-21 2001-03-19 Therapeutische anti-cytomegalovirus verbindungen

Country Status (9)

Country Link
US (3) US6579970B2 (de)
EP (2) EP1265916B1 (de)
JP (1) JP2003527847A (de)
AT (1) ATE313560T1 (de)
AU (1) AU2001245886A1 (de)
CA (1) CA2403681A1 (de)
DE (1) DE60116068T2 (de)
ES (1) ES2254387T3 (de)
WO (1) WO2001070766A2 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7902121B2 (en) * 2001-07-02 2011-03-08 The Board Of Trustees Of The Leland Stanford Junior University MHC-antigen arrays for detection and characterization of immune responses
ES2610781T3 (es) 2004-09-14 2017-05-03 Argos Therapeutics, Inc. Amplificación de patógenos independiente de la cepa y vacunas para estos
EP3156069B8 (de) 2008-06-20 2020-10-21 Duke University Zusammensetzungen, verfahren und kits zur auslösung einer immunreaktion
US9109007B2 (en) 2010-08-18 2015-08-18 Purdue Pharma L.P. MHC-I restricted epitopes containing non-natural amino acid residues
EP3049092A4 (de) 2013-09-24 2017-09-06 Duke University Zusammensetzungen, verfahren und kits zur auslösung einer immunreaktion
JP6818551B2 (ja) * 2013-12-03 2021-01-20 ホオキパ バイオテック ジーエムビーエイチ Ｃｍｖワクチン
US20180153976A1 (en) * 2015-06-18 2018-06-07 Vaximm Ag Novel cmv pp65 targeting dna vaccine for cancer immunotherapy
WO2020056152A1 (en) * 2018-09-12 2020-03-19 Chang Liu Single chain constructs
CN111748580B (zh) * 2019-03-28 2022-09-13 百奥泰生物制药股份有限公司 一种检测免疫检查点抗体活性的方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683196A (en) * 1983-12-12 1987-07-28 Meru, Inc. Method and materials for the identification of lipopolysaccharide producing microorganisms
US4754065A (en) 1984-12-18 1988-06-28 Cetus Corporation Precursor to nucleic acid probe
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5837249A (en) 1985-04-19 1998-11-17 The Wistar Institute Method for generating an immunogenic T cell response protective against a virus
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
WO1992013878A2 (en) 1991-02-07 1992-08-20 Board Of Trustees Of The University Of Illinois Conformationally restricted mimetics of beta turns and beta bulges and peptides containing the same
JPH07101999A (ja) 1993-10-06 1995-04-18 Hagiwara Yoshihide 抗癌ヒトモノクローナル抗体に対する抗イデイオタイプ抗体のアミノ酸配列およびそれをコードするｄｎａ塩基配列
US5643786A (en) 1995-01-27 1997-07-01 The United States Of America As Represented By The Department Of Health And Human Services Method for isolating dendritic cells
DE69728289T2 (de) * 1996-11-12 2005-02-24 City Of Hope, Duarte Immunreaktive ctl-peptidepitope von humanem cytomegalovirus
FR2757169B1 (fr) 1996-12-13 1999-03-05 Inst Nat Sante Rech Med Proteine de fusion comportant tout ou partie de la proteine pp65 de cmv humain, utile notamment dans la preparation d'un vaccin
ES2265165T3 (es) 1997-07-10 2007-02-01 Mannkind Corporation Dispositivo para inducir una respuesta ltc.
US8932806B1 (en) * 1998-01-19 2015-01-13 Florian Kern Method for identifying t-cell stimulating protein fragments

Also Published As

Publication number Publication date
WO2001070766A3 (en) 2002-02-14
CA2403681A1 (en) 2001-09-27
AU2001245886A1 (en) 2001-10-03
DE60116068D1 (de) 2006-01-26
US6579970B2 (en) 2003-06-17
US8029796B2 (en) 2011-10-04
ES2254387T3 (es) 2006-06-16
WO2001070766A2 (en) 2001-09-27
JP2003527847A (ja) 2003-09-24
EP1655305A2 (de) 2006-05-10
US7202331B2 (en) 2007-04-10
US20030199673A1 (en) 2003-10-23
EP1265916B1 (de) 2005-12-21
US20020058038A1 (en) 2002-05-16
EP1265916A2 (de) 2002-12-18
DE60116068T2 (de) 2006-08-17
US20090148451A1 (en) 2009-06-11
EP1655305A3 (de) 2006-09-13

Similar Documents

Publication Publication Date Title
IL228069A0 (en) Antibodies specific to fcyriib and methods of using them
DE602006020300D1 (de) Immunologische verwendungen von immunmodulatorischen verbindungen für einen impfstoff und therapie gegen infektionskrankheiten
IL201889A (en) Medication for the treatment of vaccine-related disorders containing antibodies that specifically recognize the nk 1.1 antigen or cd56 antigen expressed by nk t cells
IL195338A (en) An antibody comprising an FC variant containing amino acid replaces d or e at position 239, a medicament containing it and its use
FI1897548T4 (fi) T-solujen säätely
ZA200508389B (en) Humanized antibodies to interferon alpha receptor-1(IFNAR-1)
ATE313560T1 (de) Therapeutische anti-cytomegalovirus verbindungen
DE60109922D1 (de) Therapeutische verbindungen gegen eierstockkrebs
DE60238555D1 (de) Parathormon-antikörper und damit zusammenhängende verfahren
EP1538900A4 (de) Krebsimpfstoffe, die epitope von karzinof talen antigenen enthalten
ATE418344T1 (de) Fusionszellen und zytokin-zusammensetzungen zur behandlung von krankheiten
DE60140972D1 (de) Antigene aus Cryptosporidium parvum, Antikörper dagegen und diagnostische und therapeutische Zusammensetzungen
UA96275C2 (ru) Иммунотерапевтическое индуцирование обратного развития атеросклеротических бляшек у пациентов
WO2001068677A3 (en) Derivatives of breast canacer antigen her-2 for therapeutical use
DE60135158D1 (de) Antagonisten des ige-rezeptors
UA94211C2 (ru) Выделенное полностью человеческое моноклональное cd3 антитело
WO2002012272A3 (en) Therapeutic anti-melanoma compounds
WO2001092307A3 (en) Therapeutic compounds for ovarian cancer
WO2001070767A3 (en) Therapeutic anti-melanoma compounds
DE60111538D1 (de) Therapeutische verbindungen gegen eierstockkrebs
WO2003037264A3 (en) Therapeutic anti-hiv (vpr) compounds
WO2003051285A3 (en) Therapeutic anti-hiv (iv9) compounds
WO2004039324A3 (en) Anti-hiv (sl9) compounds
WO2004071414A3 (en) Therapeutic anti-hcv (al9) compounds
WO2002004497A3 (en) Multiple antigenic peptides immunogenic against streptococcus pneumoniae

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties